Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment
Elizabeth F. Krakow(Fred Hutch Cancer Center), Jean‐Sébastien Delisle(Hôpital Maisonneuve-Rosemont), Julie Bergeron(University of Iowa), Silvy Lachance(Hôpital Maisonneuve-Rosemont), Denis‐Claude Roy(Hôpital Maisonneuve-Rosemont)
Cited by 18
Related Papers
A common haplotype in the complement regulatory gene factor H ( <i>HF1/CFH</i> ) predisposes individuals to age-related macular degeneration
|Proceedings of the National Academy of Sciences|2005|2k
Canadian Implantable Defibrillator Study (CIDS)
|Circulation|2000|1.6k
Amiodarone to Prevent Recurrence of Atrial Fibrillation
|New England Journal of Medicine|2000|1.2k
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration
|Nature Genetics|2006|1.1k
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
|New England Journal of Medicine|2007|631